184 related articles for article (PubMed ID: 21573503)
1. Identification of characteristic molecular signature of Müllerian inhibiting substance in human HPV-related cervical cancer cells.
Hwang SJ; Suh MJ; Yoon JH; Kim MR; Ryu KS; Nam SW; Donahoe PK; Maclaughlin DT; Kim JH
Int J Oncol; 2011 Oct; 39(4):811-20. PubMed ID: 21573503
[TBL] [Abstract][Full Text] [Related]
2. Expression of Müllerian inhibiting substance type II receptor and antiproliferative effects of MIS on human cervical cancer.
Song JY; Jo HH; Kim MR; Lew YO; Ryu KS; Cha JH; Kang CS; Donahoe PK; MacLaughlin DT; Kim JH
Int J Oncol; 2012 Jun; 40(6):2013-21. PubMed ID: 22344630
[TBL] [Abstract][Full Text] [Related]
3. Mullerian inhibiting substance induces apoptosis of human endometrial stromal cells in endometriosis.
Namkung J; Song JY; Jo HH; Kim MR; Lew YO; Donahoe PK; MacLaughlin DT; Kim JH
J Clin Endocrinol Metab; 2012 Sep; 97(9):3224-30. PubMed ID: 22761458
[TBL] [Abstract][Full Text] [Related]
4. Evidence for a Müllerian-inhibiting substance autocrine/paracrine system in adult human endometrium.
Wang J; Dicken C; Lustbader JW; Tortoriello DV
Fertil Steril; 2009 Apr; 91(4):1195-203. PubMed ID: 18328480
[TBL] [Abstract][Full Text] [Related]
5. The expression of Müllerian inhibiting substance/anti-Müllerian hormone type II receptor protein and mRNA in benign, borderline and malignant ovarian neoplasia.
Song JY; Chen KY; Kim SY; Kim MR; Ryu KS; Cha JH; Kang CS; MacLaughlin DT; Kim JH
Int J Oncol; 2009 Jun; 34(6):1583-91. PubMed ID: 19424576
[TBL] [Abstract][Full Text] [Related]
6. Mullerian Inhibiting Substance inhibits cervical cancer cell growth via a pathway involving p130 and p107.
Barbie TU; Barbie DA; MacLaughlin DT; Maheswaran S; Donahoe PK
Proc Natl Acad Sci U S A; 2003 Dec; 100(26):15601-6. PubMed ID: 14671316
[TBL] [Abstract][Full Text] [Related]
7. Identification of large-scale characteristic genes of Müllerian inhibiting substance in human ovarian cancer cells.
Nam SW; Jo YS; Eun JW; Song JY; Ryu KS; Lee JY; Lee JM; Maclaughlin DT; Kim JH
Int J Mol Med; 2009 May; 23(5):589-96. PubMed ID: 19360316
[TBL] [Abstract][Full Text] [Related]
8. Enhanced purification and production of Müllerian inhibiting substance for therapeutic applications.
Donahoe PK; Clarke T; Teixeira J; Maheswaran S; MacLaughlin DT
Mol Cell Endocrinol; 2003 Dec; 211(1-2):37-42. PubMed ID: 14656474
[TBL] [Abstract][Full Text] [Related]
9. Expression of Müllerian-Inhibiting Substance/Anti-Müllerian Hormone Type II Receptor in the Human Theca Cells.
Cheon KY; Chung YJ; Cho HH; Kim MR; Cha JH; Kang CS; Lee JY; Kim JH
J Clin Endocrinol Metab; 2018 Sep; 103(9):3376-3385. PubMed ID: 29947765
[TBL] [Abstract][Full Text] [Related]
10. Mullerian inhibiting substance recruits ALK3 to regulate Leydig cell differentiation.
Wu X; Zhang N; Lee MM
Endocrinology; 2012 Oct; 153(10):4929-37. PubMed ID: 22872577
[TBL] [Abstract][Full Text] [Related]
11. Patterns of Müllerian Inhibiting Substance Type II and Candidate Type I Receptors in Epithelial Ovarian Cancer.
Basal E; Ayeni T; Zhang Q; Langstraat C; Donahoe PK; Pepin D; Yin X; Leof E; Cliby W
Curr Mol Med; 2016; 16(3):222-31. PubMed ID: 26917267
[TBL] [Abstract][Full Text] [Related]
12. Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MIS.
Masiakos PT; MacLaughlin DT; Maheswaran S; Teixeira J; Fuller AF; Shah PC; Kehas DJ; Kenneally MK; Dombkowski DM; Ha TU; Preffer FI; Donahoe PK
Clin Cancer Res; 1999 Nov; 5(11):3488-99. PubMed ID: 10589763
[TBL] [Abstract][Full Text] [Related]
13. Recombinant human Mullerian inhibiting substance inhibits long-term growth of MIS type II receptor-directed transgenic mouse ovarian cancers in vivo.
Pieretti-Vanmarcke R; Donahoe PK; Szotek P; Manganaro T; Lorenzen MK; Lorenzen J; Connolly DC; Halpern EF; MacLaughlin DT
Clin Cancer Res; 2006 Mar; 12(5):1593-8. PubMed ID: 16533786
[TBL] [Abstract][Full Text] [Related]
14. Synergistic cooperation between the beta-catenin signaling pathway and steroidogenic factor 1 in the activation of the Mullerian inhibiting substance type II receptor.
Hossain A; Saunders GF
J Biol Chem; 2003 Jul; 278(29):26511-6. PubMed ID: 12724325
[TBL] [Abstract][Full Text] [Related]
15. Endometrial cancer is a receptor-mediated target for Mullerian Inhibiting Substance.
Renaud EJ; MacLaughlin DT; Oliva E; Rueda BR; Donahoe PK
Proc Natl Acad Sci U S A; 2005 Jan; 102(1):111-6. PubMed ID: 15618407
[TBL] [Abstract][Full Text] [Related]
16. AAV9 delivering a modified human Mullerian inhibiting substance as a gene therapy in patient-derived xenografts of ovarian cancer.
Pépin D; Sosulski A; Zhang L; Wang D; Vathipadiekal V; Hendren K; Coletti CM; Yu A; Castro CM; Birrer MJ; Gao G; Donahoe PK
Proc Natl Acad Sci U S A; 2015 Aug; 112(32):E4418-27. PubMed ID: 26216943
[TBL] [Abstract][Full Text] [Related]
17. The serine/threonine transmembrane receptor ALK2 mediates Müllerian inhibiting substance signaling.
Visser JA; Olaso R; Verhoef-Post M; Kramer P; Themmen AP; Ingraham HA
Mol Endocrinol; 2001 Jun; 15(6):936-45. PubMed ID: 11376112
[TBL] [Abstract][Full Text] [Related]
18. Tanshinone IIA inhibits viral oncogene expression leading to apoptosis and inhibition of cervical cancer.
Munagala R; Aqil F; Jeyabalan J; Gupta RC
Cancer Lett; 2015 Jan; 356(2 Pt B):536-46. PubMed ID: 25304375
[TBL] [Abstract][Full Text] [Related]
19. Müllerian inhibiting substance type II receptor (MISIIR): a novel, tissue-specific target expressed by gynecologic cancers.
Bakkum-Gamez JN; Aletti G; Lewis KA; Keeney GL; Thomas BM; Navarro-Teulon I; Cliby WA
Gynecol Oncol; 2008 Jan; 108(1):141-8. PubMed ID: 17988723
[TBL] [Abstract][Full Text] [Related]
20. A B-myb--DREAM complex is not critical to regulate the G2/M genes in HPV-transformed cell lines.
Rashid NN; Yusof R; Watson RJ
Anticancer Res; 2014 Nov; 34(11):6557-63. PubMed ID: 25368258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
